Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of BI 456906 vs placebo and open-label semaglutide in type 2 diabetes mellitus
2019-002390-60Phase 2Active
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of survodutide in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Absolute change in HbA1c from baseline to 16 weeks. Started Nov 2019; status: active.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2019-002390-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002390-60.